Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 for drug discovery and mechanism of action (MOA) research

Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dalcinonacog alfa (DalcA) is being developed for the treatment of Hemophilia B. DalcA was developed using a rational design approach with three amino acid substitutions in two loops (within the Coagulation factor IX (FIX) protein to significantly enhance affinity to the cofactor VIII and stabilize activated FIX (FIXa).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-792-1mg	1mg	3090
GMP-Bios-INN-792-10mg	10mg	Inquiry
GMP-Bios-INN-792-100mg	100mg	Inquiry
GMP-Bios-INN-792-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
INN Name	Dalcinonacog Alfa
Target	F9
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa)
VD LC	F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Catalyst Biosciences, Inc. (South San Francisco CA USA) / ISU Abxis (Seoul South Korea)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0